Penumbra (NYSE:PEN) Downgraded by Leerink Partnrs to Hold

Penumbra (NYSE:PEN) was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Several other research firms have also recently commented on PEN. Citigroup cut Penumbra from a “buy” rating to a “neutral” rating and upped their price target for the stock from $350.00 to $374.00 in a research note on Thursday. Needham & Company LLC cut shares of Penumbra from a “buy” rating to a “hold” rating in a research note on Friday. William Blair downgraded shares of Penumbra from an “outperform” rating to a “market perform” rating in a research report on Thursday. Piper Sandler downgraded shares of Penumbra from an “overweight” rating to a “hold” rating and set a $374.00 target price on the stock. in a report on Thursday. Finally, Leerink Partners lowered shares of Penumbra to a “market perform” rating in a research note on Friday. Seven analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $355.88.

Penumbra Trading Up 0.1%

NYSE PEN opened at $350.93 on Thursday. The firm’s fifty day moving average is $303.54 and its two-hundred day moving average is $269.52. Penumbra has a one year low of $221.26 and a one year high of $352.15. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 6.73. The firm has a market cap of $13.74 billion, a PE ratio of 83.95, a P/E/G ratio of 2.14 and a beta of 0.71.

Penumbra (NYSE:PEN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.07. Penumbra had a return on equity of 11.35% and a net margin of 12.30%.The firm had revenue of $354.69 million for the quarter, compared to analysts’ expectations of $340.77 million. During the same quarter in the previous year, the firm posted $0.85 EPS. The firm’s revenue for the quarter was up 17.8% on a year-over-year basis. Analysts expect that Penumbra will post 3.67 earnings per share for the current year.

Insider Activity at Penumbra

In related news, Director Thomas Wilder sold 186 shares of the firm’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $310.72, for a total value of $57,793.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Johanna Roberts sold 1,800 shares of the business’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $300.06, for a total transaction of $540,108.00. Following the sale, the executive vice president directly owned 64,736 shares in the company, valued at approximately $19,424,684.16. This represents a 2.71% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 34,144 shares of company stock worth $10,260,127. 4.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Penumbra

Several institutional investors have recently modified their holdings of PEN. Vanguard Group Inc. increased its stake in Penumbra by 5.0% in the 2nd quarter. Vanguard Group Inc. now owns 3,860,655 shares of the company’s stock valued at $990,760,000 after purchasing an additional 185,306 shares in the last quarter. Geode Capital Management LLC grew its holdings in Penumbra by 2.6% in the second quarter. Geode Capital Management LLC now owns 706,404 shares of the company’s stock valued at $181,314,000 after purchasing an additional 17,772 shares during the last quarter. Invesco Ltd. increased its position in shares of Penumbra by 1,139.3% in the second quarter. Invesco Ltd. now owns 633,485 shares of the company’s stock valued at $162,571,000 after buying an additional 582,369 shares in the last quarter. Norges Bank acquired a new position in shares of Penumbra during the 2nd quarter worth $114,014,000. Finally, Thrivent Financial for Lutherans boosted its position in shares of Penumbra by 13.7% in the 3rd quarter. Thrivent Financial for Lutherans now owns 367,062 shares of the company’s stock worth $92,984,000 after buying an additional 44,185 shares in the last quarter. Hedge funds and other institutional investors own 88.88% of the company’s stock.

Penumbra News Roundup

Here are the key news stories impacting Penumbra this week:

• Positive Sentiment: Boston Scientific agreed to acquire Penumbra for $374 per share in a cash-and-stock deal, citing strategic expansion into mechanical thrombectomy and neurovascular markets — the transaction creates a significant takeover premium that lifted investor interest. Boston Scientific announces agreement to acquire Penumbra, Inc.
• Positive Sentiment: Penumbra issued preliminary Q4 and FY2025 results/guidance showing higher-than-consensus Q4 revenue guidance (~$383.0M–$384.8M vs. $361.9M consensus) and FY revenue around $1.4B — these operational beats support the deal valuation and the company’s growth profile. Penumbra provides preliminary update on Q4 and FY2025 results
• Neutral Sentiment: Wells Fargo cut its rating to Equal Weight but left a $374 price target — the target essentially aligns with the deal price, implying limited upside beyond the acquisition terms unless a competing bid emerges. Penumbra downgraded at Wells Fargo
• Neutral Sentiment: Market commentary and earnings-estimate revisions note strong recent volume and a large one-day surge; analysts point to momentum but caution on sustainability absent competing bids or further fundamentals. Zacks coverage of Penumbra price move
• Negative Sentiment: Needham downgraded Penumbra from Buy to Hold — a straightforward analyst reaction that could weigh on sentiment and aftermarket buying absent a higher competing bid. Penumbra downgraded at Needham
• Negative Sentiment: Multiple shareholder law firms (Kahn Swick & Foti, Halper Sadeh, Ademi, Brodsky & Smith, others) have opened investigations and class-action alerts alleging the sale price/process may be unfair — litigation or legal challenges could delay the deal, lead to renegotiation, or increase transaction costs. Kahn Swick & Foti investor alert on Penumbra sale

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.